A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults.

Trial Profile

A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 22 Nov 2011 Actual end date (5 Jul 2011) added as reported by European Clinical Trials Database record.
    • 16 Nov 2011 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 25 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top